The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
ECM remodeling in hypertensive heart disease
Open accessAbstract
Hypertensive heart disease (HHD) occurs in patients that clinically have both diastolic and systolic heart failure and will soon become the most common cause of heart failure. Two key aspects of heart failure secondary to HHD are the relatively highly prevalent LV hypertrophy and cardiac fibrosis, caused by changes in the local and systemic neurohormonal environment. The fibrotic state is marked by changes in the balance between MMPs and their inhibitors, which alter the composition of the ECM. Importantly, the fibrotic ECM impairs cardiomyocyte function. Recent research suggests that therapies targeting the expression, synthesis, or activation of the enzymes responsible for ECM homeostasis might represent novel opportunities to modify the natural progression of HHD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myofibroblasts and mechano-regulation of connective tissue remodelling
Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C., & Brown, R. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm809 · Cited by 4,290
Structure and function of matrix metalloproteinases and TIMPs
NAGASE, H., VISSE, R., & MURPHY, G. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.12.002 · Cited by 3,409
Desmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243
Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system
Mehta, P. K., & Griendling, K. K. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00287.2006 · Cited by 1,924
Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly.
Galis, Z. S., & Khatri, J. J. (2002) · PubMed · Cited by 1,787
Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: The Good, the Bad, and the Ugly
Galis, Z. S., & Khatri, J. J. (2002) · Circulation Research · doi:10.1161/res.90.3.251 · Cited by 1,548
Left Ventricular Hypertrophy: Pathogenesis, Detection, and Prognosis
Lorell, B. H., & Carabello, B. A. (2000) · Circulation · doi:10.1161/01.cir.102.4.470 · Cited by 1,232
Zile, M. R., & Brutsaert, D. L. (2002) · Circulation · doi:10.1161/hc1102.105289 · Cited by 1,184
Cardiac interstitium in health and disease: The fibrillar collagen network
Weber, K. T. (1989) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(89)90360-4 · Cited by 1,056
Zile, M. R., & Brutsaert, D. L. (2002) · Circulation · doi:10.1161/hc1202.105290 · Cited by 887
Cited by
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
Acute Kidney Injury and Chronic Kidney Disease as Interconnected Syndromes
Chawla, L. S., Eggers, P. W., Star, R. A., & Kimmel, P. L. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1214243 · Cited by 1,977
Irbesartan in patients with heart failure and preserved ejection fraction
Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., Anderson, S., Donovan, M., Iverson, E., Staiger, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805450 · Cited by 1,960
The pathogenesis of cardiac fibrosis
Kong, P., Christia, P., & Frangogiannis, N. G. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1349-6 · Cited by 1,567
Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases
Wynn, T. A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31487 · Cited by 1,456
Frangogiannis, N. G. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa324 · Cited by 1,229
“Myocardial fibrosis, the expansion of the cardiac interstitium due to net accumulation of ECM proteins, accompanies most cardiac pathologic conditions.(2,3) Although in most myocardial diseases, the extent of car-”
BackgroundFibroblasts in fibrosis: novel roles and mediators
Kendall, R. T., & Feghali-Bostwick, C. A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00123 · Cited by 1,082
The Progression of Hypertensive Heart Disease
Drazner, M. H. (2011) · Circulation · doi:10.1161/circulationaha.108.845792 · Cited by 844
Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities
Frangogiannis, N. G. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.07.001 · Cited by 841
Duisters, R. F., Tijsen, A. J., Schroen, B., Leenders, J. J., Lentink, V., van der Made, I., Herias, V., van Leeuwen, R. E., Schellings, M. W., Barenbrug, P., et al. (2009) · Circulation Research · doi:10.1161/circresaha.108.182535 · Cited by 816
Ghosh, A. K., & Vaughan, D. E. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.22783 · Cited by 679
Cellular mechanotransduction in health and diseases: from molecular mechanism to therapeutic targets
Di, X., Gao, X., Peng, L., Ai, J., Jin, X., Qi, S., Li, H., Wang, K., & Luo, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01501-9 · Cited by 622
Extracellular Matrix Molecules: Potential Targets in Pharmacotherapy
Järveläinen, H., Sainio, A., Koulu, M., Wight, T. N., & Penttinen, R. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001289 · Cited by 566
MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets
van Rooij, E., & Olson, E. N. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33099 · Cited by 553
Dobaczewski, M., Gonzalez-Quesada, C., & Frangogiannis, N. G. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2009.07.015 · Cited by 548
The extracellular matrix in myocardial injury, repair, and remodeling
Frangogiannis, N. G. (2017) · Journal of Clinical Investigation · doi:10.1172/jci87491 · Cited by 524
Wong, T. C., Piehler, K., Meier, C. G., Testa, S. M., Klock, A. M., Aneizi, A. A., Shakesprere, J., Kellman, P., Shroff, S. G., Schwartzman, D. S., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.089409 · Cited by 493
Periostin is essential for cardiac healingafter acute myocardial infarction
Shimazaki, M., Nakamura, K., Kii, I., Kashima, T., Amizuka, N., Li, M., Saito, M., Fukuda, K., Nishiyama, T., Kitajima, S., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071297 · Cited by 461
Matricellular Proteins in Cardiac Adaptation and Disease
Frangogiannis, N. G. (2012) · Physiological Reviews · doi:10.1152/physrev.00008.2011 · Cited by 445
Yu, L., Ruifrok, W. P. T., Meissner, M., Bos, E. M., van Goor, H., Sanjabi, B., van der Harst, P., Pitt, B., Goldstein, I. J., Koerts, J. A., et al. (2013) · Circulation: Heart Failure · doi:10.1161/circheartfailure.112.971168 · Cited by 435
Microfabricated tissue gauges to measure and manipulate forces from 3D microtissues
Legant, W. R., Pathak, A., Yang, M. T., Deshpande, V. S., McMeeking, R. M., & Chen, C. S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900174106 · Cited by 434
Extracellular matrix remodeling and cardiac fibrosis
Li, L., Zhao, Q., & Kong, W. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.01.013 · Cited by 419
Wang, C., Zhang, C., Liu, L., A, X., Chen, B., Li, Y., & Du, J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.09.001 · Cited by 412
Fibroblasts in the Infarcted, Remodeling, and Failing Heart
Humeres, C., & Frangogiannis, N. G. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.02.006 · Cited by 410
Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart
Creemers, E. E., & Pinto, Y. M. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvq308 · Cited by 403
Toward MicroRNA–Based Therapeutics for Heart Disease: The Sense in Antisense
van Rooij, E., Marshall, W. S., & Olson, E. N. (2008) · Circulation Research · doi:10.1161/circresaha.108.183426 · Cited by 377
Segura, A. M., Frazier, O. H., & Buja, L. M. (2014) · Heart Failure Reviews · doi:10.1007/s10741-012-9365-4 · Cited by 371
Interleukin-1 Receptor Type I Signaling Critically Regulates Infarct Healing and Cardiac Remodeling
Bujak, M., Dobaczewski, M., Chatila, K., Mendoza, L. H., Li, N., Reddy, A., & Frangogiannis, N. G. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070974 · Cited by 365
TGF-β-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases
Pardali, E., Sanchez-Duffhues, G., Gomez-Puerto, M., & Ten Dijke, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102157 · Cited by 360
Cardiac Aging: From Molecular Mechanisms to Significance in Human Health and Disease
Dai, D.-F., Chen, T., Johnson, S. C., Szeto, H., & Rabinovitch, P. S. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4179 · Cited by 334
“Pathological ECM remodeling, especially interstitial fibrosis, increases cardiac stiffness and reduces cardiac compliance as well as disrupts the coordination of myocardial excitation-contraction coupling [reviewed by Berk (32) and Spinale (301)].”
BackgroundCommon risk factors for heart failure and cancer
Meijers, W. C., & de Boer, R. A. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz035 · Cited by 314
The role of IL-1 in the pathogenesis of heart disease
Bujak, M., & Frangogiannis, N. G. (2009) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-009-0024-y · Cited by 307
G-Protein–Coupled Receptors in Heart Disease
Wang, J., Gareri, C., & Rockman, H. A. (2018) · Circulation Research · doi:10.1161/circresaha.118.311403 · Cited by 303
Li, Z., Zhu, S., Liu, Q., Wei, J., Jin, Y., Wang, X., & Zhang, L. (2020) · Environmental Pollution · doi:10.1016/j.envpol.2020.115025 · Cited by 301
MicroRNA-22 Regulates Cardiac Hypertrophy and Remodeling in Response to Stress
Huang, Z.-P., Chen, J., Seok, H. Y., Zhang, Z., Kataoka, M., Hu, X., & Wang, D.-Z. (2013) · Circulation Research · doi:10.1161/circresaha.112.300682 · Cited by 292
D'Urso, M., & Kurniawan, N. A. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.609653 · Cited by 280
Extracellular matrix degradation in liver fibrosis: Biochemistry and regulation
Iredale, J. P., Thompson, A., & Henderson, N. C. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.11.002 · Cited by 269
Xia, Y., Lee, K., Li, N., Corbett, D., Mendoza, L., & Frangogiannis, N. G. (2009) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0541-5 · Cited by 264
Myostatin Directly Regulates Skeletal Muscle Fibrosis
Li, Z. B., Kollias, H. D., & Wagner, K. R. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802585200 · Cited by 262
Inhibiting Fibronectin Attenuates Fibrosis and Improves Cardiac Function in a Model of Heart Failure
Valiente-Alandi, I., Potter, S. J., Salvador, A. M., Schafer, A. E., Schips, T., Carrillo-Salinas, F., Gibson, A. M., Nieman, M. L., Perkins, C., Sargent, M. A., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034609 · Cited by 261
Nrf2 Protects Against Maladaptive Cardiac Responses to Hemodynamic Stress
Li, J., Ichikawa, T., Villacorta, L., Janicki, J. S., Brower, G. L., Yamamoto, M., & Cui, T. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.189480 · Cited by 253
Nox enzymes as novel targets for drug development
Lambeth, J. D., Krause, K.-H., & Clark, R. A. (2008) · Seminars in Immunopathology · doi:10.1007/s00281-008-0123-6 · Cited by 212
Selman, M., & Pardo, A. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101393 · Cited by 211
Extracellular matrix alterations in hypertensive vascular remodeling
Lemarié, C. A., Tharaux, P.-L., & Lehoux, S. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2009.09.018 · Cited by 192
Self-citationIncreased afterload induces pathological cardiac hypertrophy: a new in vitro model
Hirt, M. N., Sörensen, N. A., Bartholdt, L. M., Boeddinghaus, J., Schaaf, S., Eder, A., Vollert, I., Stöhr, A., Schulze, T., Witten, A., et al. (2012) · Basic Research in Cardiology · doi:10.1007/s00395-012-0307-z · Cited by 154
View from the heart: cardiac fibroblasts in development, scarring and regeneration
Furtado, M. B., Nim, H. T., Boyd, S. E., & Rosenthal, N. A. (2016) · Development · doi:10.1242/dev.120576 · Cited by 144
The role of Smad signaling cascades in cardiac fibrosis
Hanna, A., Humeres, C., & Frangogiannis, N. G. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109826 · Cited by 132
Fibrous scaffolds for building hearts and heart parts
Capulli, A. K., MacQueen, L. A., Sheehy, S. P., & Parker, K. K. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.11.020 · Cited by 130
Zhou, X., Ma, L., Habibi, J., Whaley-Connell, A., Hayden, M. R., Tilmon, R. D., Brown, A. N., Kim, J.-A., DeMarco, V. G., & Sowers, J. R. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.145136 · Cited by 116
The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target
Steckelings, U. M., Widdop, R. E., Sturrock, E. D., Lubbe, L., Hussain, T., Kaschina, E., Unger, T., Hallberg, A., Carey, R. M., & Sumners, C. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000281 · Cited by 97
Li, R., & Frangogiannis, N. G. (2022) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2022.07.006 · Cited by 62
Delfín, D. A., Zang, K. E., Schill, K. E., Patel, N. T., Janssen, P. M. L., Raman, S. V., & Rafael-Fortney, J. A. (2012) · Neuromuscular Disorders · doi:10.1016/j.nmd.2012.05.002 · Cited by 27
“Increased MMPs and reduced TIMPs are often concurrent in human cardiac pathology, and reduced TIMP levels correlate with worsened cardiac outcomes [8, 14, 43, 44].”
BackgroundCalcium and Vitamin D Supplementation. Myths and Realities with Regard to Cardiovascular Risk
Muscogiuri, G., Barrea, L., Altieri, B., Di Somma, C., Bhattoa, H. P., Laudisio, D., Duval, G. T., Pugliese, G., Annweiler, C., Orio, F., et al. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190408165805 · Cited by 27
Fibroblasts slow conduction velocity in a reconstituted tissue model of fibrotic cardiomyopathy
Spencer, T. M., Blumenstein, R. F., Pryse, K. M., Lee, S.-L., Glaubke, D. A., Carlson, B. E., Elson, E. L., & Genin, G. M. (2017) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.6b00576 · Cited by 23
Metadata
- Authors
- Berk, B. C., Fujiwara, K., & Lehoux, S.
- Venue
- Journal of Clinical Investigation
- Published
- 2007-03-01
- Volume
- 117
- Issue
- 3
- Pages
- 568-575
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2060072724
- Cited by
- 902
- References
- 75
- FWCI
- 26.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.